Prolongation of cardiac ventricular repolarization under paliperidone: How and how much?

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 6, 2011, Pages 690-695

  Vigneault, Patrick ^a,b   Kaddar, Nisrin ^a,b   Bourgault, Sarah ^a,b   Caillier, Bertrand ^a,b   Pilote, Sylvie ^a,b   Patoine, Dany ^a,b   Simard, Chantale ^a,b   Drolet, Benoit ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

action potentials; HERG blocker; paliperidone; QT prolongation; ventricular repolarization

Indexed keywords

PALIPERIDONE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAM; EMBRYO; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IC 50; ISOLATED HEART; MALE; NONHUMAN; PATCH CLAMP; PERFUSION; PRIORITY JOURNAL; QT PROLONGATION; RAT; TELEMETRY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CARDIAC PACING, ARTIFICIAL; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE ANTAGONISTS; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HEART; HEK293 CELLS; HUMANS; ISOXAZOLES; KCNQ1 POTASSIUM CHANNEL; MALE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIMIDINES; RECOMBINANT PROTEINS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; VENTRICULAR DYSFUNCTION;

EID: 79958259478     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318217d941     Document Type: Article

References (16)

1. Kleinhaus K, Harlap S, Perrin M, et al. Age, sex and first treatment of schizophrenia in a population cohort. J Psychiatr Res. 2011;45:136-141.
2. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatr. 2008;69:817-829. (Pubitemid 351838691)
3. Paliperidone (InvegaTM) monograph. Toronto, Ontario, Canada: Janssen- Ortho Inc. 2009.
4. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent. Prescrire Int. 2007;16:236-237.
5. Hough DW, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25-34.
6. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998; 97:204-210. (Pubitemid 28124679)
7. Van de Water A, Verheyen J, Xhonneux R, et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Meth. 1989;22:207-217. (Pubitemid 19275446)
8. Sakaguchi Y, Takahara A, Nakamura Y, et al. Halothane-anaesthetized, closed-chest, guinea-pig model for assessment of drug-induced QTinterval prolongation. Basic Clin Pharmacol Toxicol. 2009;104:43-48.
9. De Clerck F, Van de WA, D'Aubioul J, et al. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol. 2002;16:125-140. (Pubitemid 34587797)
10. Crumb WJ Jr, Ekins S, Sarazan RD, et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res. 2006;23:1133-1143. (Pubitemid 43946136)
11. Drolet B, Yang T, Daleau P, et al. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol. 2003;41:934-937. (Pubitemid 36706143)
12. Titier K, Deridet E, Moore N. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone. Toxicol Appl Pharmacol. 2002; 180:145-149. (Pubitemid 34478557)
13. Roden DM. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol. 2000;11:938-940. (Pubitemid 30663004)
14. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 2001; 24:323-351. (Pubitemid 32417533)
15. Eichelbaum M, Kroemer HK, Fromm MF. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev. 1997;27:171-199. (Pubitemid 27417872)
16. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310-322.